OMNISCAN™ IV injection solution 0.5mmol/ml (15ml), vial 10pcs

OMNISCAN™ 0.5mmol Solution 15ml Buy Online

OMNISCAN IV Injection Solution: A Comprehensive Overview

OMNISCAN, a vital tool in modern medical imaging, offers enhanced visualization of internal structures during Magnetic Resonance Imaging (MRI) scans. Its crucial role in diagnosing various conditions makes understanding its properties and applications paramount for healthcare professionals.

What is OMNISCAN?

OMNISCAN is a non-ionic, paramagnetic contrast agent used intravenously to improve the clarity of MRI scans. It contains gadodiamide, a gadolinium-based compound that enhances the contrast between different tissues, leading to more detailed images.

Gadodiamide, the active ingredient in OMNISCAN, works by shortening the relaxation times of protons in tissues. This results in a significant increase in signal intensity during MRI, making it easier to differentiate between healthy and diseased tissue. The enhancement is primarily in the extracellular space.

OMNISCAN is employed to improve the visualization of various anatomical structures and pathologies. Its use is broad, including brain and spinal cord imaging, as well as the visualization of blood vessels (MRA) in areas like the kidneys and aorta.

Dosage varies depending on the specific application and patient factors. It’s crucial to follow the prescribed dosage and administration guidelines meticulously. Typically administered as a bolus intravenous injection, often followed by a saline flush to ensure complete delivery.

OMNISCAN is a sterile, clear, colorless to slightly yellow aqueous solution. Each ml contains gadodiamide 287 mg (equivalent to 0.5 mmol). The solution’s non-ionic nature contributes to its generally good safety profile compared to older ionic contrast agents.

• Enhanced Image Quality: Provides superior contrast resolution for improved diagnostic accuracy.
• Wide Range of Applications: Suitable for various MRI examinations, including neuroimaging and MRA.
• Generally Well-Tolerated: Often exhibits a favorable safety profile compared to some other contrast agents.

• Potential for Nephrogenic Systemic Fibrosis (NSF): Although rare, NSF is a serious risk in patients with severe kidney impairment.
• Allergic Reactions: While uncommon, allergic reactions, ranging from mild to severe, can occur.
• Specific Contraindications: OMNISCAN is contraindicated in patients with certain kidney conditions.

Contraindications and Precautions

Severe kidney disease (GFR < 30 mL/min/1.73m²) and acute kidney injury are absolute contraindications. Caution is advised in patients with a history of allergic reactions to contrast agents or other relevant medical conditions. Careful monitoring is necessary after administration.

This information is for educational purposes only and does not constitute medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.

What is OMNISCAN?

OMNISCAN, specifically the 0.5 mmol/ml intravenous injection solution, is a crucial contrast agent used in Magnetic Resonance Imaging (MRI) procedures. Its primary function is to enhance the visibility of internal organs and tissues, significantly improving the diagnostic capabilities of MRI scans. This enhancement is achieved through its unique interaction with the body’s magnetic fields, allowing radiologists to obtain clearer and more detailed images.

The active ingredient in OMNISCAN is gadodiamide, a gadolinium-based chelate. This compound possesses paramagnetic properties, meaning it interacts with the magnetic fields used in MRI. This interaction alters the signal received by the MRI scanner, resulting in improved contrast between different tissues and structures within the body. The improved contrast is essential for identifying abnormalities and assisting in accurate diagnosis.

Unlike some older contrast agents, OMNISCAN is a non-ionic formulation. This characteristic contributes to its generally improved safety profile and reduced risk of adverse reactions, although potential side effects still exist and should be carefully considered. The non-ionic nature also aids in its rapid distribution and excretion from the body, minimizing the duration of its presence in the system. OMNISCAN is packaged in sterile vials, typically containing 15ml of solution, ready for intravenous administration under the guidance of a healthcare professional.

In essence, OMNISCAN serves as a powerful diagnostic tool, improving the quality and effectiveness of MRI scans, ultimately aiding healthcare providers in providing more accurate diagnoses and effective treatment plans. Its non-ionic nature and proven efficacy have established it as a valuable asset in modern medical imaging practices. However, understanding its potential side effects and contraindications remains crucial for safe and effective use.

Mechanism of Action

OMNISCAN’s effectiveness stems from the unique properties of its active ingredient, gadodiamide. This compound is a paramagnetic chelate of gadolinium, a rare earth element with a strong magnetic moment. When administered intravenously, gadodiamide distributes into the extracellular fluid space, affecting the relaxation times of water protons within tissues.

The paramagnetic nature of gadodiamide alters the magnetic environment surrounding water molecules in the body. This interaction significantly shortens the T1 relaxation time of these protons. In simpler terms, it speeds up the rate at which the protons realign with the magnetic field of the MRI scanner after being excited by radio waves.

This accelerated relaxation process leads to a marked increase in signal intensity on T1-weighted MRI images. Areas where gadodiamide has accumulated appear brighter, creating a stark contrast against surrounding tissues. This enhanced contrast dramatically improves the visualization of blood vessels, lesions, and other anatomical structures, making subtle abnormalities more easily detectable.

The precise mechanism involves the interaction of the unpaired electrons in the gadolinium ion with the magnetic moments of nearby water protons. This interaction facilitates energy transfer, accelerating the relaxation process and consequently enhancing the MRI signal. The non-ionic nature of the gadodiamide molecule contributes to its generally favorable safety profile compared to older ionic contrast agents, although potential risks remain.

Therefore, OMNISCAN’s mechanism relies on the paramagnetic properties of gadodiamide to manipulate the MRI signal, resulting in significantly improved image contrast and diagnostic clarity. This enhancement allows for better detection and characterization of various pathological processes and anatomical structures.

Uses and Applications

OMNISCAN’s versatility extends across a wide range of MRI applications, significantly enhancing diagnostic capabilities in various medical specialties. Its primary use is as a contrast agent to improve the visualization of anatomical structures and pathological processes during MRI examinations. The enhanced contrast allows for more precise identification and characterization of abnormalities, leading to improved diagnostic accuracy.

In neuroimaging, OMNISCAN plays a crucial role in visualizing brain tumors, strokes, multiple sclerosis lesions, and other neurological conditions. The improved contrast resolution allows for better delineation of these lesions from surrounding healthy tissue, facilitating more precise diagnosis and treatment planning. This is particularly valuable in identifying subtle changes or lesions that might otherwise be missed on unenhanced MRI.

Beyond neuroimaging, OMNISCAN finds significant utility in body MRI. Its application extends to the visualization of various organs and systems, including the kidneys, liver, and musculoskeletal system. The agent’s ability to enhance the contrast of blood vessels makes it invaluable in Magnetic Resonance Angiography (MRA), facilitating the assessment of arterial stenosis, aneurysms, and other vascular abnormalities.

Specifically, OMNISCAN is used to visualize the kidneys, aiding in the diagnosis of renal masses, cysts, and other renal pathologies. Its application in MRA allows for detailed visualization of renal and aorto-iliac arteries, assisting in the diagnosis of vascular diseases. The enhanced visualization capabilities of OMNISCAN contribute to improved diagnostic confidence and more informed treatment strategies across a broad spectrum of medical conditions.

In summary, OMNISCAN’s diverse applications in neuroimaging, body MRI, and MRA demonstrate its importance as a versatile contrast agent. Its ability to enhance image quality leads to more accurate diagnoses and improved patient care across various medical specialties. The improved visualization of subtle abnormalities ensures more effective treatment planning and monitoring.

Dosage and Administration

The administration of OMNISCAN requires careful adherence to prescribed guidelines, as dosage varies depending on the specific clinical indication and patient characteristics. It is crucial that healthcare professionals strictly follow the recommended protocols to ensure both efficacy and patient safety. Improper dosage or administration can lead to suboptimal image quality or, in more serious cases, adverse events.

OMNISCAN is typically administered intravenously as a bolus injection. This method delivers the contrast agent rapidly into the bloodstream, ensuring quick distribution to the target tissues. The bolus injection is often followed by a saline flush of the intravenous line, which helps to clear any residual contrast agent from the tubing and ensure complete delivery of the prescribed dose. This ensures that the full dose reaches the intended area for optimal image enhancement.

Dosage calculations frequently involve the patient’s weight, often expressed as milliliters or millimoles per kilogram (mL/kg or mmol/kg). Precise dosage is determined by the radiologist or physician based on factors such as the specific clinical indication, the patient’s renal function, and other relevant medical conditions. Deviation from the recommended dosage should only be made under the direct supervision and guidance of a qualified medical professional.

For example, in adult patients undergoing renal imaging, a common dosage might be 0.2 mL/kg, administered as a rapid intravenous bolus. However, pediatric patients may receive a lower dose, adjusted according to their weight and age. The specific dosage instructions will be clearly outlined in the accompanying product information sheet and should be carefully reviewed before administration. Pre-administration assessment of renal function is also critical, especially given the potential for nephrogenic systemic fibrosis (NSF).

In summary, the proper administration of OMNISCAN involves a precise dosage tailored to the individual patient and clinical context. Adherence to established protocols, including bolus injection and saline flush, is essential for optimal results and patient safety. Always consult the product information for complete and up-to-date dosage guidelines.

Composition and Properties

OMNISCAN IV injection solution is a meticulously formulated contrast agent, its precise composition contributing significantly to its efficacy and safety profile. The key component is gadodiamide, a gadolinium-based chelate. This compound, present at a concentration of 0.5 mmol/ml, is responsible for the contrast enhancement observed during MRI scans. The precise chemical structure of gadodiamide ensures optimal interaction with the magnetic fields used in MRI.

Gadodiamide’s structure is crucial; it’s a non-ionic compound. This characteristic differentiates it from older ionic contrast agents, which were associated with a higher risk of adverse reactions. The non-ionic nature minimizes potential interactions with cellular components, resulting in a generally improved safety profile. This reduced risk of adverse reactions is a significant advantage for patients undergoing MRI procedures.

Beyond gadodiamide, OMNISCAN contains other excipients that contribute to its stability and injectability. These excipients are carefully selected to ensure the solution’s sterility, clarity, and overall suitability for intravenous administration. The solution itself is a clear, colorless to slightly yellow aqueous liquid, practically free from particulate matter, ensuring a smooth and safe injection process.

The solution’s physical properties, such as viscosity and osmolarity, are carefully controlled to optimize its intravenous administration and distribution within the body. These properties are critical for ensuring even distribution of the contrast agent, contributing to the consistency and reliability of MRI image enhancement. The non-ionic nature also facilitates rapid excretion from the body, minimizing the duration of the contrast agent’s presence in the circulatory system.

In summary, OMNISCAN’s composition, characterized by its non-ionic gadodiamide base and carefully selected excipients, results in a contrast agent with desirable physical properties, ensuring both efficacy and a generally favorable safety profile. The precise control of its composition and properties is critical for the reliable and safe use of OMNISCAN in MRI procedures.

Pros

OMNISCAN offers several key advantages that contribute to its widespread use as a contrast agent in MRI. Its primary benefit lies in its ability to significantly enhance the quality of MRI images, leading to more accurate and detailed diagnoses. This improved visualization is particularly crucial in identifying subtle abnormalities that might otherwise be missed on unenhanced scans, ultimately leading to better patient outcomes.

The non-ionic nature of OMNISCAN is a significant advantage. This characteristic contributes to a generally improved safety profile compared to older ionic contrast agents, reducing the risk of adverse reactions such as allergic reactions or nephrotoxicity. This improved safety profile is particularly beneficial for patients with pre-existing conditions or those at increased risk of complications. Consequently, OMNISCAN allows for wider patient applicability.

OMNISCAN demonstrates broad applicability across various MRI examinations. Its use extends beyond neuroimaging to encompass a wide range of body MRI applications. This versatility makes it a valuable tool for radiologists and physicians across multiple specialties, enhancing diagnostic capabilities in various clinical contexts. The comprehensive applicability streamlines workflow for healthcare professionals.

Furthermore, OMNISCAN’s rapid distribution and excretion from the body minimize its overall duration of presence in the circulatory system. This characteristic is a significant advantage for patients, reducing the potential for prolonged exposure to the contrast agent and minimizing the potential for long-term side effects. This rapid clearance contributes to its overall favorable safety profile and patient comfort.

In summary, the benefits of using OMNISCAN include superior image enhancement leading to more precise diagnoses, a reduced risk of adverse reactions due to its non-ionic nature, broad applicability across diverse MRI applications, and rapid clearance from the body. These advantages combine to make OMNISCAN a valuable asset in modern medical imaging.

Important Note

Cons

While OMNISCAN offers significant advantages in MRI contrast enhancement, it’s crucial to acknowledge potential drawbacks. Although generally well-tolerated, the possibility of adverse reactions exists, ranging from mild to severe. These reactions can manifest as allergic responses, such as hives, itching, or shortness of breath, necessitating immediate medical attention. The frequency of these reactions is relatively low, but the potential for severity necessitates careful monitoring of patients post-administration.

A more serious, though rare, potential risk associated with gadolinium-based contrast agents is Nephrogenic Systemic Fibrosis (NSF). This debilitating condition primarily affects patients with severe kidney impairment (GFR < 30 mL/min/1.73m²). NSF is characterized by fibrosis and thickening of the skin and other tissues. Therefore, careful assessment of renal function is paramount before administering OMNISCAN to any patient, and its use is contraindicated in those with severely compromised kidney function.

Other potential side effects, while less severe, can include headaches, nausea, and vomiting. These symptoms are generally transient and resolve without specific intervention. However, their occurrence should be documented and appropriately managed. Prompt reporting of any adverse events to the appropriate authorities is crucial for continuous safety monitoring and improvement of clinical practice.

Furthermore, the cost of OMNISCAN, like other contrast agents, can be a factor in healthcare resource allocation. While the improved diagnostic accuracy often outweighs the cost, budget constraints might influence its use in certain healthcare settings. The cost-effectiveness of OMNISCAN should always be considered in the context of the specific clinical situation and the potential benefits to the patient.

In summary, although OMNISCAN provides valuable diagnostic enhancement, potential adverse reactions, the risk of NSF in patients with renal impairment, the occurrence of less severe side effects, and cost considerations should be carefully weighed against the benefits before administration. Appropriate patient selection and careful monitoring are crucial for minimizing potential risks.